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Neuroleptic Malignant Syndrome, with 
Attention to Its Occurrence with Atypical 
Antipsychotic Medication: A Review 
 




The neuroleptic malignant syndrome (NMS) is an idiopathic, life-threatening reaction to 
antipsychotic medication.  NMS was traditionally attributed to potent dopamine 
antagonism of typical antipsychotics, but cases of NMS have now been reported for each of 
the newer antipsychotics.  When NMS is caused by a newer, atypical antipsychotic the 
presentation differs somewhat; fever, rigidity, and, possibly, death may be less frequent.  
Diagnostic features, predisposing factors, and treatment are discussed, as is the important 
matter of reinstituting antipsychotic treatment.  
  
   Neuroleptic malignant syndrome (NMS) is an idiosyncratic, life-threatening 
reaction to antipsychotic medication, characterized principally by delirium, fever, 
autonomic instability, and muscular rigidity (1). Most cases occur within a month 
of starting the medication, two-thirds within the first week. NMS develops in 0.02-
2.44 percent of patients who are prescribed antipsychotics (2-4); NMS may occur 
even when doses are in the therapeutic range; the risk is somewhat greater with 
rapid dose escalation and with parenteral administration.    
   Hyperthermia, delirium, autonomic instability, and extrapyramidal symptoms in 
a person treated with antipsychotic medications should prompt consideration of 
NMS.  Classically, the extrapyramidal symptoms of NMS manifest as “lead pipe” 
rigidity of the limbs; other extrapyramidal signs, such as tremor, and cogwheeling, 
may be present.  The muscular rigidity leads to rhabdomyolysis, which can in turn 
result in renal failure.  A wide range of mental status presentations are possible, but 
patients are most often mute and stuporous.   Laboratory findings include 
leukocytosis (most often 10-20,000, thought to be a stress response) elevated 
creatine kinase (can reach 100,000), hypocalcemia (from muscle sequestration of 
calcium), moderate elevations of LDH, AST and ALT, and elevated serum 
osmolarity from dehydration.  An EEG may show generalized slowing, consistent 
with delirium (5).  Symptoms generally develop over 24-72 hours and, in 
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uncomplicated cases, the mean duration of symptoms is 13-15 days, longer if 
caused by a depot medication (2). Serious complications are possible, including 
renal failure, thromboembolism, respiratory failure from chest wall rigidity, 
aspiration pneumonia, and arrhythmia (5).  
   DSM IV-TR criteria (6) for diagnosing NMS are in Table 1.  A slightly different 
set of criteria, proposed by Levenson (5), is also commonly employed (Table 2).   
 
 
Table 1. DSM IV-TR Diagnostic Criteria for NMS  
Severe muscle rigidity and elevated temperature associated with the use of neuroleptic 
medication as well as 2 or more of the following 
   Diaphoresis 
   Dysphagia 
   Tremor 
   Incontinence 
   Changes in level of consciousness ranging from confusion to coma 
   Mutism 
   Tachycardia 
   Elevated or labile blood pressure 
   Leukocytosis 
   Laboratory evidence of muscle injury 
 
 
Table 2.  Levenson’s criteria for the diagnosis of NMS* 
Major criteria   
        fever  
        rigidity  
        elevated creatine kinase (CK) 
Minor criteria  
        tachycardia  
        abnormal blood pressure  
        altered consciousness 
        diaphoresis  
        leukocytosis  
* 3 major criteria, or 2 major and 4 minor criteria, are required for diagnosis   
 
 
   In the differential diagnosis, infectious, metabolic and neurologic conditions 
should be considered, depending on associated clinical features (Table 3). An 
interesting debate has centered around the similarities and differences between 
malignant catatonia and NMS.  These two conditions, affecting a similar patient 
population, can be so similar in their presenting features that some have argued 
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that they are variants on a spectrum (7).  Because NMS, malignant catatonia, and 
serotonin syndrome are difficult to distinguish on symptomatic presentation alone, 
medication history, behavioral prodrome, and timeline of symptom-evolution will 
be critical to making a diagnosis.   
 
Table 3.  Differential Diagnosis 
Diagnosis Suggestive Clinical Features, Indicated Lab Testing 
Infectious: meningitis, 
encephalitis, bacteremic sepsis 
Lumbar puncture.  Consider blood and urine cultures 
depending on overall clinical picture 
Metabolic: thyrotoxicosis, 
pheochromocytoma 
Check TSH, urine catacholamines and metanephrines 
Neurologic: nonconvulsive 
status epilepticus, postictal 
state 
EEG  
Drug intoxications: MDMA, 
cocaine, amphetamines 
Urine toxicology 
Serotonin syndrome Associated with gastrointestinal signs and symptoms 
(hyperactive bowel sounds, diarrhea, vomiting), myoclonus, 
hyperreflexia 
Lithium toxicity Check lithium level. Myoclonus, hyperreflexia, tremor 
Central anticholinergic 
syndrome 
Dry, flushed skin, diminished sweating, urinary retention, 
dilated pupils 
Malignant hyperthermia Exposure to halogenated anesthetics 
Malignant or lethal catatonia Associated with hyperpyrexia, rigidity, akinesia.  Review 
behavior changes over previous weeks.  May be preceded 
by emotional withdrawal, anxiety, agitation, stereotypies, 
posturing, waxy flexibility, mutism. 
Neuroleptic-induced heat 
stroke 
Suggestive history: warm environment, abrupt onset, no 
extrapyramidal signs, may have absence of diaphoresis if 




   NMS is an idiosyncratic reaction and cannot be predicted, but there are some 
identified risk factors.  Young age, male gender, dehydration, agitation, rapid dose-
escalation, and intra-muscular administration increase the risk (5,8). Prior NMS 
increases the risk for future episodes.  There is some evidence for an association 
between NMS and the following (9,10): concurrent lithium treatment, poorly 
controlled extrapyramidal symptoms, patients with affective disorders, iron 
deficiency, poor nutrition, environmental heat load, catatonia, and those drugs that 
are more potent dopamine-2 (D2) antagonists.   
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Pathogenesis 
   The pathogenesis of NMS is unknown.  Observation that NMS occurred with D2 
blocking agents lead to the hypothesis that D2 blockade in various regions of the 
brain explained the presentation: D2 action in the reticular activating system could 
cause changes in level of consciousness;  D2 blockade in the nigrostriatal pathway 
could cause rigidity; D2 blockade in the hypothalamus could account for 
autonomic instability and impaired heat dissipation, thus hyperpyrexia from the 
combination of hypothalamic dysfunction and muscle rigidity (9-11). This theory 
is now challenged since atypical antipsychotics, with their lower D2 potency, are 
reported to cause NMS.      
 
NMS and Atypical Antipsychotics 
   There have been reports of NMS attributed to each of the atypical antipsychotics 
and all of these medications are listed in the NMS Information Services’ Registry 
(9).  The rates and presenting symptoms of NMS in typical versus atypical 
antipsychotics have not been directly compared (12), but some observations are 
possible from available information.  Of the 55 “probable” or “definite” cases of 
NMS reported to the Neuroleptic Malignant Syndrome Information Service 
between 1998 and 2002, 31 patients (56%) were on a typical antipsychotic; 24 
patients (44%) were on an atypical antipsychotic (13).   Cases of NMS have been 
reported with even the least potent D2 antagonist, clozapine (2,14). 
   NMS owing to atypical antipsychotics has possibly a different presentation 
compared with the traditional syndrome: less extreme CK and temperature 
elevations and less common and milder rigidity (14,15).  A 2003 review of 68 
reported cases of NMS from atypical antipsychotics found that the mean peak CK 
was 5958 and the mean maximum temperature was 38.8.  Seventy eight percent of 
patients had extrapyramidal symptoms.  Twelve of the 68 required intensive care 
and 3 patients died (2).  This mortality rate is less than that historically reported in 
NMS (11,16). Perhaps resulting from improved supportive care, mortality in NMS 
is declining overall: from 76% prior to 1970 to 11% in a 1989 study, (2,11,17).  
 
Treatment   
   If NMS is suspected, immediately discontinue all antipsychotic medication, as 
well as other D2 blocking agents.  A medical work-up should be initiated (see 
above): NMS is a diagnosis of exclusion.  Supportive care is the mainstay of 
treatment for NMS and it should occur in a setting in which  blood pressure, 
cardiac rhythm, and pulse-oximetry can be continuously monitored.   Autonomic 
instability may manifest as hypertension, hypotension, tachycardia, or cardiac 
arrhythmia.  Chest wall rigidity can compromise respiration sufficiently to require 
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intubation; intubation may also be indicated for severe aspiration pneumonia.  
Urine alkalinization and adequate support with intravenous fluids may prevent 
renal failure from myoglobinuria (18). Hyperthermia may require a cooling 
blanket.  Because hyperthermia in NMS is not mediated by pyrogens, antipyretic 
medications are generally not helpful (1).  Laryngeal dystonia, dysphagia, 
respiratory distress, or delirium may preclude oral intake, so intravenous fluid and 
parenteral nutrition may be needed (1). Prophylactic measures for deep venous 
thrombosis and frequent repositioning will decrease the likelihood of 
complications from rigidity and prolonged immobility (5).  The medication list 
should be reviewed: anticholinergic agents or other drugs that interfere with heat 
dissipation should be discontinued  (1). 
   Medication may hasten response to supportive therapy and decrease mortality 
(19,20), but controlled clinical trials do not exist, and drug studies that are 
available have not always shown benefit (21).  The two most commonly used 
pharmacologic interventions are bromocriptine, a central dopamine agonist, and 
dantrolene, which facilitates skeletal muscle relaxation via calcium release from 
the sarcoplasmic reticulum (5,9,22).  Dantrolene is available in a parenteral form; 
bromocriptine can only be administered orally.  Symptoms of NMS sometimes 
return if treatment is discontinued before complete clearance of the offending 
medication, so, if bromocriptine, dantrolene, or both are utilized, treatment should 
be continued for ten days beyond the resolution of symptoms, or for 2-3 weeks if 
the offending agent has been an extended release depot antipsychotic (5). 
   Oral or intravenous benzodiazepine, the mainstay of early treatment of catatonia, 
may decrease fever and rigidity in NMS, in addition to treating agitation (1). 
Respiratory status should be monitored. Positive results have been reported with 
diazepam (23) and lorazepam (24).  
   Electroconvulsive therapy (ECT) is another treatment option and may decrease 
hyperpyrexia, diaphoresis, and delirium, possibly by modulating dopamine activity 
in the brain.  Onset of response, on average, is after 4 treatments (12).  ECT should 
be considered especially for patients who have not improved after 48 hours of 
pharmacologic treatment, if it is not clear whether the cause of the symptoms is 
neuroleptic malignant syndrome or malignant catatonia, and if the underlying 
psychiatric diagnosis is a mood disorder (12,25-28).  
 
Antipsychotic treatment after NMS  
   Patients with a history of NMS are likely to require future antipsychotic 
treatment. The estimated risk of developing NMS again with repeat exposure to a 
D2 blocker is 30%, and the risk of mortality from subsequent NMS episodes is 
estimated to be as high as 20%) (13).  Treatment decisions are further complicated 
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by the observation that not all patients will experience a recurrence, even if they 
are treated with the same drug.   
    There are very few formal studies documenting the outcome of antipsychotic 
treatment after NMS.  Several reviews of this topic were written in the late 1980s 
(28-30, 32). For example, Olmstead reviewed 29 rechallenges reported in the 
literature; 13 of the 29 had a recurrence, and 2 of those patients died; the most 
common agent used for rechallenge was the low potency agent thioridazine (13 of 
29 patients, causing 2 recurrences of NMS, one culminating in death) (29). 
Rechallenges that produce recurrence of NMS are reported with a variety of 
medications. Rechallenge at least 2 weeks after the initial episode appears to be 
safer, and recurrence is more likely if high potency medication or high doses are 
used (1).  In a 1989 review, Rosebush and colleagues report that 13 of 15 patients 
with prior NMS experienced no recurrence on rechallenge (30). And two small, 
longer-term reviews found that in a majority of patients who are rechallenged with 
antipsychotic medication NMS does not recur (31,32).   
   Based on these reviews, on the observed risk factors for NMS, and on theoretical 
speculation about pathogenesis, we come to the following as recommendations for 
reinstituting treatment after the first episode, with the understanding that the 
evidence supporting them is limited. Weigh risks, benefits, and alternatives to 
antipsychotic medication. If alternatives are poor and the benefit outweighs the 
risk, restart antipsychotic after a 4-week waiting period following the resolution of 
the episode. Begin with a low dose, advance slowly toward the target dose, and 
choose an agent with low D2-nigrostriatal affinity (an atypical or a low potency 
typical).   Monitor carefully for fever, autonomic instability, mental status change, 
extrapyramidal symptoms, and dehydration. Serial measurements of white blood 
cell count and CK are warranted. Agitation should be treated aggressively with 
benzodiazepine, since agitation increases the risk for NMS.  Adjunctive treatment 
with a mood stabilizer, antidepressant, or both for affective symptoms may 
minimize, possibly, the required dose of antipsychotic (22,29,33). Velamoor has 
suggested considering prophylaxis with amantadine or bromocriptine (22).    
 
 
SOURCE INFORMATION  
From the University of Massachusetts Medical School, Department of Psychiatry, Worcester, MA (SG) and the 
Hospital Traumatologico y Quirurgico Prof. Juan Bosch El Pino, La Vega, Dominican Republic (RP). Address 
queries to Dr Guzofski: guzofsks@ummhc.org. 
  
 
Jefferson Journal of Psychiatry, Volume 20, Number 1 ISSN 1935-0783 
© 2006 by the authors 
On the Web:  jdc.jefferson.edu/jeffjpsychiatry  59 
REFERENCES  
1. Susman VL. Clinical management of neuroleptic malignant syndrome. 
Psychiatry Q 2001; 72:325-336  
2. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic 
malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 
65:464-470 
3. Berardi D, Amore M, Keck PE,Jr, Troia M, Dell'Atti M. Clinical and 
pharmacologic risk factors for neuroleptic malignant syndrome: A case-control 
study. Biol Psychiatry 1998; 44:748-754 
4. Khan M, Farver D. Recognition, assessment and management of neuroleptic 
malignant syndrome. South Dakota J Med 2000; 53:395-400 
5. Bhanushali MJ, Tuite PJ. The evaluation and management of patients with 
neuroleptic malignant syndrome. Neurol Clin 2004; 22:389-411 
6. American Psychiatric Association. Diagnostic and Statistical Manual, Fourth 
Edition (Text Revision) 2000 
7. Fink M. Neuroleptic malignant syndrome and catatonia: One entity or two? Biol 
Psychiatry 1996; 39:1-4 
8. Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study of neuroleptic 
malignant syndrome. Am J Psychiatry 1997; 154:1156-1158 
9. Pelonero AL, Levenson JL, Silverman JJ. Neuroleptic therapy following 
neuroleptic malignant syndrome. Psychosomatics 1985; 26:946-947 
10. Velamoor VR. Neuroleptic malignant syndrome. recognition, prevention and 
management. Drug Safety 1998; 19:73-82 
11. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J 
Anaesth 2000; 85:129-135 
12. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant 
syndrome: A review and report of cases. Aust N Z J Psychiatry 1999; 33:650-659 
13. Caroff SN. Neuroleptic malignant syndrome:  Still a risk but which patients 
may be in danger? Current Reviews in Psychiatry 2003; 12 
14. Sachdev P, Kruk J, Kneebone M, Kissane D. Clozapine-induced neuroleptic 
malignant syndrome: Review and report of new cases. J Clin Psychopharmacol 
1995; 15:365-371 
 
Jefferson Journal of Psychiatry, Volume 20, Number 1 ISSN 1935-0783 
© 2006 by the authors 
On the Web:  jdc.jefferson.edu/jeffjpsychiatry  60 
15. Karagianis JL, Phillips LC, Hogan KP, LeDrew KK. Clozapine-associated 
neuroleptic malignant syndrome: Two new cases and a review of the literature. 
Ann Pharmacother 1999; 33:623-630 
16. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 
1993; 77:185-202 
17. Lappa A, Podesta M, Capelli O, Castagna A, Di Placido G, Alampi D, 
Semeraro F. Successful treatment of a complicated case of neuroleptic malignant 
syndrome. Intensive Care Med 2002; 28:976-977 
18.  Lappa A, Podesta M, Capelli O, Castagna A, Di Placido G, Alampi D, 
Semeraro F. Successful treatment of a complicated case of neuroleptic malignant 
syndrome. Intensive Care Med 2002; 28:976-977 
19. Rosenberg MR, Green M. Neuroleptic malignant syndrome. review of response 
to therapy. Arch Intern Med 1989; 149:1927-1931 
20. Sakkas P, Davis JM, Janicak PG, Wang ZY. Drug treatment of the neuroleptic 
malignant syndrome. Psychopharmacol Bull 1991; 27:381-384 
21. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant 
syndrome. are dantrolene and bromocriptine useful adjuncts to supportive care? Br 
J Psychiatry 1991; 159:709-712 
22. Velamoor VR. Neuroleptic malignant syndrome. recognition, prevention and 
management. Drug Safety 1998; 19:73-82 
23.  Kumar V. A case of neuroleptic malignant syndrome treated with diazepam. 
Can J Psychiatry 1987; 32:815-816 
24. Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in 
the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc 
Psychiatry 1992; 31:1161-1164 
25. Caroff SN, Mann SC, Keck PE,Jr. Specific treatment of the neuroleptic 
malignant syndrome. Biol Psychiatry 1998; 44:378-381 
26. Davis JM, Janicak PG, Sakkas P, Gilmore C, Wang Z. Electroconvulsive 
therapy in the treatment of the neuroleptic malignant syndrome. Convuls Ther 
1991; 7:111-120 
27. Nisijima K, Ishiguro T. Electroconvulsive therapy for the treatment of 
neuroleptic malignant syndrome with psychotic symptoms: A report of five cases. 
J ECT 1999; 15:158-163 
 
Jefferson Journal of Psychiatry, Volume 20, Number 1 ISSN 1935-0783 
© 2006 by the authors 
On the Web:  jdc.jefferson.edu/jeffjpsychiatry  61 
28. Susman VL, Addonizio G. Recurrence of neuroleptic malignant syndrome. J 
Nerv Ment Dis 1988; 176:234-241 
29. Olmsted TR. Neuroleptic malignant syndrome: Guidelines for treatment and 
reinstitution of neuroleptics. South Med J 1988; 81:888-891 
30. Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after 
neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry 1989; 50:295-298 
31. Pope HG,Jr, Aizley HG, Keck PE,Jr, McElroy SL. Neuroleptic malignant 
syndrome: Long-term follow-up of 20 cases. J Clin Psychiatry 1991; 52:208-212 
32. Levenson JL, Fisher JG. Long-term outcome after neuroleptic malignant 
syndrome. J Clin Psychiatry 1988; 49:154-156 
33. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: 
a review. Psychiatr Serv 1998; 49:1163-1172 
 
